参附注射液联合磷酸肌酸钠治疗扩张型心肌病心功能不全的疗效观察

目的：探讨参附注射液联合磷酸肌酸钠治疗扩张型心肌病心功能不全患者的临床疗效。方法选取2014年1月—2015年6月的72例扩张型心肌病合并心功能不全患者为研究对象行回顾性分析，按照治疗方法的不同分为 A 组（36例）和 B 组（36例）。两组均进行常规抗心力衰竭治疗，A 组进行参附注射液联合磷酸肌酸钠治疗，B组静脉滴注磷酸肌酸钠治疗。分别于治疗前、治疗后14 d 观察两组的心功能分级、测定6 min 步行试验（6 minute walk test，6MWT）、进行明尼苏达心力衰竭生活质量问卷（Minnesota living with heart failure questionaire，MLHFQ）、血清 B 型利钠肽（B-type natriuretic peptide，BNP）水平、左心室收缩功能相关参数，并统计用药过程中的不良反应情况。结果两组患者治疗后14 d 临床症状均好转，但 A 组总有效率高于 B 组（ P ﹤0.05）；6MWT 距离和射血分数高于 B 组（ P ﹤0.05）；MLHFQ 评分、血清 BNP 和左心室收缩末期及舒张末期内径水平低于 B 组（ P ﹤0.05）。且无明显不良反应。结论扩张型心肌病合并心功能不全患者应用参附注射液和磷酸肌酸钠联合治疗，可以安全、有效地改善患者的临床症状，提高生活质量。

Effect Observation on Shenfu Injection Combined with Creatine Phospate in Treatment of Cardiac Inadequacy of Patients with Dilated Cardiomyopathy

Objective To investigate curative effect of Shenfu injection combined with Creatine Phospate in treatment of cardiac inadequacy of patients with dilated cardiomyopathy. Methods Clinical data of 72 patients with di-lated cardiomyopathy associated by cardiac inadequacy during January 2014 and June 2015 was retrospectively analyzed. The patients were divided into group A(n = 36)and group B(n = 36)according to different therapeutic methods. All patients received routine anti-heart failure therapy. Group A was treated with Shenfu injection combined with Creatine Phospate,while group B was injected with Creatine Phospate intravenously. Before treatment and 14 d after treatment, cardiac functional grading and 6-minute walking test(6MWT)were filled;Minnesota Living With Heart Failure Ques-tionnaire(MLHFQ)was also filled;serum B-type natriuretic peptide(BNP)levels and related parameters of left ventric-ular systolic function were detected;adverse reactions during treatment were statistically analyzed in the two groups. Re-sults Clinical symptoms in the two groups were alleviated 14 days after treatment,but the total effective rate in group A was higher than that in group B( P ﹤ 0. 05). Compared with those in group B,values of 6MWT distance and ejection fraction were higher(P ﹤ 0. 05);Values of MLHFQ score,serum BNP level,left ventricular end systolic and diastolic diameters were lower than those in group B(P ﹤ 0. 05). No obviously adverse reaction was found in two groups. Conclu-sion Shenfu injection combined with Creatine Phospate in treatment of cardiac inadequacy of patients with dilated car-diomyopathy can safely and effectively improve clinical symptoms and the quality of life.